Alvotech and Teva Pharmaceuticals (“Teva”) announced that the U.S. Food and Drug Administration (FDA) has accepted for review ...
The firm submitted data from a Phase III study showing the combination improved outcomes compared to Opdivo and chemo alone.
Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a ...
The application was based on results from the three-arm Phase 3 CheckMate -8HW study.
Squibb announced that the U.S. FDA has accepted the supplemental biologics license application for Opdivo plus Yervoy as a ...
The Federal Circuit recently issued decisions in a pair of appeals that provide guidance about when international filers of abbreviated ...
Alvotech and Teva Pharmaceuticals announced the US Food and Drug Administration (FDA) has accepted for review a Biologics ...
In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg. Teva also ...
has accepted for review the Biologics License Application (BLA) of Lerodalcibep to reduce low-density lipoprotein cholesterol (LDL-C) for the treatment of patients with atherosclerotic ...
Minnesota’s cannabis regulatory agency announced Wednesday it will begin accepting business license applications on Feb. 18. The Office of Cannabis Management will accept applications until March 14 ...
The Minnesota Office of Cannabis Management(OCM) has announced it will be accepting applications for Cannabis business licenses later this month. From Feb. 18 until March 14, OCM says it will ...